PCOLCE2 Antibody

What is PCOLCE2 and why are antibodies against it important in research?

PCOLCE2 (Procollagen C-Endopeptidase Enhancer 2) is a 415-amino acid protein containing an N-terminal signal sequence, two CUB domains, and an NTR domain. This secreted glycoprotein has been identified as a multifunctional extracellular matrix protein with complex roles in collagen processing .

• At low concentrations: Moderately enhances procollagen C-propeptide cleavage

• At higher concentrations: Significantly inhibits BMP-1 cleavage activity

PCOLCE2 antibodies are crucial research tools for investigating these concentration-dependent effects and understanding PCOLCE2's roles in normal development and pathological conditions including fibrosis and rheumatoid arthritis.

What are the primary applications for PCOLCE2 antibodies?

PCOLCE2 antibodies are versatile tools with several validated applications:

When selecting an antibody for a specific application, researchers should check validation data for each application and optimize conditions for their specific experimental system .

What is the expected molecular weight of PCOLCE2 in Western blot analysis?

This discrepancy between calculated and observed molecular weights is due to O-glycosylation and potentially other post-translational modifications. When performing Western blot analysis, researchers should expect to observe a band around 52 kDa rather than the calculated 45.7 kDa .

How should PCOLCE2 antibodies be validated for specificity and cross-reactivity?

A robust validation strategy for PCOLCE2 antibodies should include:

• Positive and negative control tissues/cells: Based on known expression patterns, high expression should be detected in heart, trabecular meshwork, pituitary gland, bladder, mammary gland, trachea, and placenta .

• Cross-reactivity testing: Verify reactivity with human, mouse, and/or rat PCOLCE2 as specified in the antibody documentation .

• Knockout/knockdown controls: Where possible, use PCOLCE2 knockout or siRNA-mediated knockdown samples as negative controls .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm specific binding.

• Multiple antibody comparison: Use different antibodies recognizing distinct epitopes within PCOLCE2 to confirm specificity.

• Recombinant protein detection: Confirm detection of recombinant PCOLCE2 at the appropriate molecular weight .

Validation should be performed for each application (WB, IHC, ICC/IF) as antibody performance can vary between applications.

What are the optimal sample preparation methods for PCOLCE2 detection?

Sample preparation methods vary by application:

For Western Blotting:

• Complete cell lysis is essential using RIPA or similar buffers

• Add protease inhibitors to prevent degradation

• For secreted PCOLCE2, collect cell culture media and concentrate if necessary

• Denaturation at 95°C for 5 minutes in standard loading buffer is typically sufficient

For Immunohistochemistry:

• Formalin-fixed paraffin-embedded (FFPE) tissues are suitable

• Heat-induced epitope retrieval (HIER) at pH 6 is recommended

• Standard deparaffinization and rehydration protocols apply

For Immunocytochemistry/Immunofluorescence:

• Fixation with paraformaldehyde followed by permeabilization with Triton X-100 works well

• Alternatively, ice-cold methanol fixation has been successfully used with certain PCOLCE2 antibodies

• Background blocking with BSA or serum is important to minimize non-specific binding

Given PCOLCE2's glycosylation status, researchers should be cautious about using deglycosylation treatments if studying native PCOLCE2.

How can researchers differentiate between PCOLCE1 and PCOLCE2 when using antibodies?

Differentiating between PCOLCE1 and PCOLCE2 is crucial given their structural similarities but distinct functions:

• Epitope selection: Choose antibodies raised against regions with low sequence homology between PCOLCE1 and PCOLCE2. The percent identity between domains is:

  • CUB1 domains: ~59% identity

  • CUB2 domains: ~54% identity

  • Linker regions: Significant differences in length and composition

  • NTR domains: ~50% identity

• Validation testing: Test antibodies against recombinant PCOLCE1 and PCOLCE2 to confirm specificity.

• Molecular weight differences: PCOLCE1 and PCOLCE2 have slightly different molecular weights that can be distinguished in high-resolution Western blots.

• Tissue expression patterns: Use known differential expression patterns - PCOLCE2 is highly expressed in heart and certain other tissues, while PCOLCE1 has a more ubiquitous expression pattern .

• Immunoblotting confirmation: Use antibodies specific to PCOLCE1 to confirm there is no cross-contamination as demonstrated in supplementary validation data from studies .

How can PCOLCE2 antibodies be utilized to study its role as a BMP-1 inhibitor?

Recent research has identified PCOLCE2 as the endogenous specific inhibitor of BMP-1/tolloid-like proteinases (BTPs) . To investigate this role:

• In vitro inhibition assays: Use purified recombinant PCOLCE2 and BMP-1 to study inhibition kinetics with various BMP-1 substrates (thrombospondin-1, betaglycan, chordin, endorepellin, and LDLR) .

• Co-immunoprecipitation: Use PCOLCE2 antibodies to pull down protein complexes and detect association with BMP-1, confirming their direct interaction.

• Domain-specific analysis: Compare the inhibitory activity of full-length PCOLCE2 versus its isolated domains (CUB1CUB2 and NTR). Research has shown that the CUB1CUB2 domains of PCOLCE2 can fully recapitulate the activity of full-length PCOLCE2 .

• Concentration-dependent effects: Set up assays with varying PCOLCE2:BMP-1 ratios to observe the transition from enhancement to inhibition. Maximum inhibition has been reported to reach 50% at a 6:1 ratio .

• Immunolocalization: Use PCOLCE2 antibodies for ICC/IF to determine co-localization with BMP-1 and its substrates in cellular contexts.

This approach allows researchers to dissect the molecular mechanisms underlying PCOLCE2's inhibitory activity and its physiological significance.

What methodological approaches can be used to investigate the role of anti-PCOLCE antibodies in rheumatoid arthritis diagnosis?

Recent research has identified anti-citrullinated PCOLCE antibodies as potential biomarkers for seronegative rheumatoid arthritis (RA) . To investigate this:

• Patient cohort studies: Test sera from:

  • RA patients (both seropositive and seronegative)

  • Healthy controls

  • Patients with other rheumatic diseases

• Detection methods: Develop ELISA or other immunoassays using:

  • Citrullinated PCOLCE peptides (particularly PCOLCE 271-284)

  • Non-citrullinated controls

  • Validated PCOLCE antibodies as standards/controls

• Diagnostic performance analysis:

  • Sensitivity: Research shows 51.53% sensitivity for anti-PCOLCE in RA

  • Specificity: 93.60% specificity has been reported

  • Positive rates in seronegative RA: 40.00% in anti-CCP negative RA, 38.76% in RF negative RA, and 36.46% in double-negative RA

• Combination testing: Evaluate the combined diagnostic value of anti-PCOLCE with standard tests:

  • Anti-PCOLCE + anti-CCP shows 82.14% sensitivity and 90.21% specificity

• Correlation analysis: Investigate correlations between anti-PCOLCE levels and:

  • CRP levels (positive correlation reported)

  • Anti-CCP levels (positive correlation reported)

  • RF levels (positive correlation reported)

This methodological framework enables comprehensive evaluation of anti-PCOLCE antibodies as diagnostic biomarkers for seronegative RA.

How can researchers investigate the concentration-dependent dual role of PCOLCE2 in collagen processing?

PCOLCE2 exhibits a concentration-dependent dual role in collagen processing - enhancing at low concentrations while inhibiting at higher concentrations. To investigate this:

• Dose-response experiments: Set up in vitro procollagen processing assays with:

  • Recombinant BMP-1

  • Procollagen substrate (types I or II)

  • Varying concentrations of PCOLCE2

  • Controls with PCOLCE1 for comparison

• Domain mapping: Produce and test PCOLCE2 constructs:

  • Full-length PCOLCE2

  • CUB domains (CUB1CUB2)

  • NTR domain

  • Constructs with protease cleavage sites for domain separation

• Competitive binding assays: Investigate if PCOLCE2 competes with procollagen for BMP-1 binding at higher concentrations.

• Structural analysis: Use antibodies that recognize specific domains to determine which regions are involved in enhancement versus inhibition.

• In vivo models: Compare collagen processing in:

  • Wild-type animals

  • PCOLCE2 knockout models

  • PCOLCE2 overexpression models

Research has shown that while PCOLCE1 exhibits a stable enhancement factor of 1.7 across concentration ratios, PCOLCE2 shows maximum enhancement of only 1.3-fold at low concentrations but transitions to 50% inhibition at higher ratios .

What techniques can be employed to study the subcellular localization and trafficking of PCOLCE2?

Understanding the subcellular localization and trafficking of PCOLCE2 is crucial for elucidating its functional roles:

• Immunofluorescence microscopy:

  • Co-staining with organelle markers (ER, Golgi, secretory vesicles)

  • Live-cell imaging with fluorescently tagged PCOLCE2

  • Fixation optimization: PFA/Triton X-100 or ice-cold methanol

• Subcellular fractionation:

  • Western blotting of different cellular fractions

  • Density gradient centrifugation followed by immunodetection

• Secretion analysis:

  • Pulse-chase experiments with metabolic labeling

  • Collection and analysis of conditioned media

  • Brefeldin A treatment to block secretion

• Trafficking inhibition studies:

  • Temperature blocks (e.g., 20°C block for TGN exit)

  • Chemical inhibitors of specific trafficking steps

  • Dominant-negative Rab protein expression

• Glycosylation assessment:

  • Endoglycosidase H sensitivity for ER-to-Golgi transit

  • PNGase F treatment to remove all N-glycans

  • O-glycosylation analysis using specific inhibitors or enzymes

Published data shows PCOLCE2 localization to both nucleoplasm and cytosol in U-2 OS cells, and strong cytoplasmic staining in glandular cells of prostate and trophoblastic cells of placenta .

How can researchers study the interaction between PCOLCE2 and HDL metabolism through apolipoprotein A-I processing?

PCOLCE2 has been reported to enhance the removal of a propeptide from proapolipoprotein A-I (proapoA-I), facilitating the production of mature apoA-I, the major protein component of plasma high-density lipoprotein (HDL) . To investigate this role:

• In vitro processing assays:

  • Purify recombinant proapoA-I

  • Incubate with recombinant PCOLCE2 at various concentrations

  • Analyze processing by SDS-PAGE and Western blotting

  • Compare with BMP-1 processing of proapoA-I

• Cell-based studies:

  • Overexpress or knockdown PCOLCE2 in hepatocytes or macrophages

  • Measure apoA-I secretion and maturation

  • Analyze HDL formation using density gradient ultracentrifugation

• Co-immunoprecipitation:

  • Use PCOLCE2 antibodies to pull down protein complexes

  • Detect association with proapoA-I or mature apoA-I

  • Identify other potential components of the processing complex

• Animal models:

  • Analyze apoA-I processing and HDL levels in PCOLCE2 knockout mice

  • Perform liver-specific overexpression of PCOLCE2

  • Measure plasma lipid profiles and atherosclerosis development

• Human studies:

  • Investigate correlation between PCOLCE2 levels (using antibody-based assays) and HDL parameters in patient cohorts

  • Examine genetic variants in PCOLCE2 and their association with HDL metabolism

This research avenue could provide insights into novel mechanisms regulating HDL metabolism and potential therapeutic targets for dyslipidemia.

What approaches can be used to study the role of PCOLCE2 in fibrotic diseases using antibody-based techniques?

Given PCOLCE2's role in collagen processing, investigating its involvement in fibrotic diseases is highly relevant:

• Tissue expression analysis:

  • Compare PCOLCE2 levels in normal versus fibrotic tissues using IHC

  • Quantify expression changes using image analysis software

  • Co-stain with fibrosis markers (α-SMA, collagen I, fibronectin)

• Cell culture models:

  • Study PCOLCE2 expression and secretion in fibroblasts from normal and fibrotic tissues

  • Analyze the effect of profibrotic stimuli (TGF-β, PDGF) on PCOLCE2 expression

  • Investigate the impact of PCOLCE2 knockdown/overexpression on collagen production

• Mechanistic studies:

  • Examine PCOLCE2's dual role (enhancement/inhibition) in the context of fibrosis

  • Investigate if the balance between PCOLCE1 and PCOLCE2 is altered in fibrotic conditions

  • Study the interaction between PCOLCE2 and other ECM components in fibrotic tissues

• Therapeutic potential:

  • Test antibodies against PCOLCE2 as potential anti-fibrotic agents

  • Develop peptide inhibitors based on PCOLCE2 binding epitopes

  • Evaluate gene therapy approaches to modulate PCOLCE2 expression

• Biomarker development:

  • Assess circulating PCOLCE2 levels as potential biomarkers for fibrosis progression

  • Correlate PCOLCE2 levels with clinical parameters and outcomes

  • Develop sensitive ELISA assays using well-characterized PCOLCE2 antibodies

This multifaceted approach can provide insights into PCOLCE2's role in fibrotic pathologies and potential therapeutic strategies.

How should researchers design experiments to investigate potential therapeutic applications of targeting PCOLCE2?

Based on PCOLCE2's roles in collagen processing, BMP-1 inhibition, and its potential involvement in rheumatoid arthritis, several therapeutic approaches could be explored:

• Target validation studies:

  • Use PCOLCE2 knockout or conditional knockout models to establish phenotypic relevance

  • Perform tissue-specific overexpression to evaluate potential adverse effects

  • Validate in multiple disease models (fibrosis, arthritis, cardiovascular)

• Therapeutic antibody development:

  • Generate function-blocking antibodies targeting specific PCOLCE2 domains

  • Evaluate antibody specificity using various PCOLCE2 constructs

  • Test in cell-based and animal models of relevant diseases

• Small molecule screening:

  • Develop high-throughput assays using PCOLCE2 antibodies for detection

  • Screen for compounds that modulate PCOLCE2-BMP-1 interaction

  • Validate hits using secondary functional assays

• Peptide-based approaches:

  • Design peptides mimicking the CUB domains that show inhibitory activity

  • Test competitive binding to BMP-1 or procollagen

  • Evaluate stability and delivery methods in vivo

• Gene therapy approaches:

  • Develop CRISPR-based methods to modulate PCOLCE2 expression

  • Evaluate viral vector delivery to target tissues

  • Monitor effects on ECM remodeling using PCOLCE2 antibodies

• Biomarker development for patient stratification:

  • Establish sensitive assays for anti-PCOLCE2 autoantibodies

  • Correlate with disease activity and treatment response

  • Integrate with other biomarkers for improved diagnostic accuracy

Each approach requires careful validation using well-characterized PCOLCE2 antibodies to confirm target engagement and functional outcomes.

What are common issues when using PCOLCE2 antibodies and how can they be resolved?

The loss rate of PCOLCE2 antibody activity can be significant during storage, as determined by accelerated thermal degradation tests (37°C for 48h) . Proper storage at -20°C with glycerol and avoiding repeated freeze-thaw cycles is recommended for maintaining antibody performance.

How can researchers optimize PCOLCE2 antibody performance across different experimental systems?

Optimizing PCOLCE2 antibody performance requires systematic approach:

• Antibody selection:

  • Choose antibodies validated for your specific application (WB, IHC, ICC/IF)

  • Consider polyclonal antibodies for detection and monoclonal antibodies for specific epitope targeting

  • Select appropriate host species to avoid cross-reactivity in your experimental system

• Sample-specific optimization:

  • For cell lines: Determine PCOLCE2 expression levels through database mining

  • For tissues: Consider fixation effects on epitope accessibility

  • For recombinant proteins: Account for tags that might affect antibody binding

• Application-specific considerations:

  • Western blot: Optimize protein loading (50-100 μg), transfer conditions, and blocking reagents

  • IHC: Test different antigen retrieval methods (HIER pH 6 recommended)

  • ICC/IF: Compare different fixation methods (PFA/Triton X-100 or methanol)

• Titration experiments:

  • Test a range of antibody dilutions:

    • WB: 1:500-1:6000

    • IHC: 1:50-1:200

    • ICC/IF: 0.25-2 μg/mL

• Controls and validation:

  • Include positive control samples (tissues with known high expression)

  • Use negative controls (secondary antibody alone, pre-immune serum)

  • Consider peptide competition assays to confirm specificity